Loading
HKSEHealthcareBiotechnology
Latest quote
HK$47.50
−HK$1.34 · -2.74%
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Latest quote
HK$47.50
−HK$1.34 · -2.74%
Regular session · HKT · Market data may be delayed.
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Day range
Current HK$47.50
52-week range
Current HK$47.50
Regular session · HKT · Market data may be delayed.
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
Day range
Current HK$47.50
52-week range
Current HK$47.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 21.79B CNY | 18.68B CNY | 17.03B CNY | 15.27B CNY | 10.29B CNY |
| Cost of goods sold | 11.77B CNY | 11.02B CNY | 10.21B CNY | 8.54B CNY | 5.46B CNY |
| Gross profit | 10.02B CNY | 7.65B CNY | 6.83B CNY | 6.72B CNY | 4.83B CNY |
| Research and development | 860.13M CNY | 766.44M CNY | 792.58M CNY | 682.82M CNY | 501.58M CNY |
| Selling, general, and administrative | 2.45B CNY | 2.15B CNY | 1.79B CNY | 1.43B CNY | 1B CNY |
| Operating expenses | 3.38B CNY | 2.68B CNY | 2.38B CNY | 2.38B CNY | 1.64B CNY |
| Interest income | 384.37M CNY | 350.37M CNY | 219.18M CNY | 107.48M CNY | 58.03M CNY |
| Interest expense | 139.36M CNY | 157.59M CNY | 158.49M CNY | 64.38M CNY | 39.19M CNY |
| Depreciation and amortization | 1.28B CNY | 1.44B CNY | 1.17B CNY | 800.67M CNY | 481.78M CNY |
| Operating income | 6.64B CNY | 4.97B CNY | 4.45B CNY | 4.34B CNY | 3.19B CNY |
| Net income | 4.91B CNY | 3.36B CNY | 3.4B CNY | 4.42B CNY | 3.39B CNY |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Nov 16, 2020 | 3:1 | — | — |
Effective Nov 16, 2020
3:1
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS272.35M0.04%646.2B USD0.05%$86.455-1.09%
Vanguard FTSE Emerging Markets ETFVWO259.18M0.15%162.3B USD0.06%$60.095-1.27%
iShares Core MSCI Emerging Markets ETFIEMG251.52M0.15%163.85B USD0.09%$81.8301-1.71%
iShares Core MSCI China ETF2801.HK108.18M0.88%12.38B HKD0.20%HK$23.84-1.57%
iShares Core MSCI Asia ex Japan ETF3010.HK72.38M0.19%35.89B HKD0.28%HK$91.34-1.02%
Avantis Emerging Markets Equity ETFAVEM69.75M0.24%28.93B USD0.33%$94.4649-1.64%
JPMorgan BetaBuilders Developed Asia Pacific ex-Japan ETFBBAX68.9M1.01%6.86B USD0.19%$63.53-1.44%
Global X China Biotech ETF (HKD)2820.HK62.64M10.75%681.52M HKD0.68%HK$71.34-2.30%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGiShares Core MSCI China ETF2801.HKiShares Core MSCI Asia ex Japan ETF3010.HKAvantis Emerging Markets Equity ETFAVEMJPMorgan BetaBuilders Developed Asia Pacific ex-Japan ETFBBAXGlobal X China Biotech ETF (HKD)2820.HKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
